OpenAI VP Max Schwarzer joins Anthropic amid recent kerfuffle
Key AI safety researcher jumps ship to competitor following recent leadership shakeup and strategic disagreements.
In a significant move within the AI industry, Max Schwarzer, a Vice President of Research at OpenAI, has departed to join its primary competitor, Anthropic. Schwarzer was a prominent researcher focused on AI safety and alignment, contributing to critical projects like reinforcement learning from human feedback (RLHF). His exit follows a period of notable internal turbulence at OpenAI, including the high-profile disbanding of its 'Superalignment' team dedicated to controlling superintelligent AI, which raised questions about the company's long-term safety priorities. This personnel shift underscores the intense competition for top AI talent and highlights ongoing strategic divergences between leading labs.
Schwarzer's deep expertise in scalable oversight and reward modeling is a major coup for Anthropic, a company founded by former OpenAI safety researchers with a core mission centered on its 'Constitutional AI' framework. His move signals Anthropic's continued commitment to recruiting researchers who prioritize safety-by-design, potentially accelerating their development of Claude models. For OpenAI, losing a senior safety researcher to a direct rival amid recent scrutiny represents a reputational and strategic challenge. The defection amplifies the narrative of a deepening rift between commercial product development and long-term safety research within the field, setting the stage for an even more competitive landscape in both capability and safety innovation.
- OpenAI VP and safety research lead Max Schwarzer has joined competitor Anthropic.
- The move follows OpenAI's recent dissolution of its 'Superalignment' team, causing internal and external concern.
- Schwarzer's expertise in RLHF and alignment will directly strengthen Anthropic's Constitutional AI safety approach.
Why It Matters
Accelerates the AI safety talent war, potentially shifting the balance in how leading labs approach alignment and commercial strategy.